In vivo brain imaging of tangle burden in humans
- 78 Downloads
Cerebral neurofibrillary tangles (NFTs) accumulate in a predictable sequence decades before the clinical symptoms of Alzheimer’s disease emerge, and the degree of tangle degeneration correlates with the severity of cognitive impairment. A valid in vivo marker of tangle burden, therefore, would be useful for presymptomatic and symptomatic disease detection and treatment monitoring. Recent advances using positron emission tomography (PET) indicate the feasibility of in vivo imaging that provides a combined signal of both neurofibrillary tangles and senile plaques. Such results are encouraging that a tangle-specific marker will be found; however, several methodological issues first need to be addressed, including scanner spatial resolution in the relatively small brain regions where tangles accumulate. NFT-specific imaging probes will need to be lipophilic in order to cross the blood-brain barrier and neuronal membranes and have a high binding affinity to NFTs with minimal nonspecific binding, which would result in a high signal-to-background ratio in PET images.
Index EntriesAlzheimer’s disease positron emission tomography cerebral glucose metabolism neurofibrillary tangles
Unable to display preview. Download preview PDF.
- Barrio J. R., Huang S.-C., Cole G. M., Satyamurthy N., Petric A., and Small G. W. (1999) PET imaging of tangles and plaques in Alzheimer disease. J. Nucl. Med. 40(Suppl.), 70P-71P.Google Scholar
- Braak E., Griffing K., Arai K., Bohl J., Bratzke H., and Braak H. (1999) Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur. Arch. Psychiatry Clin. Neurosci. 249(Suppl. 3), III/14-III/22.Google Scholar
- Gotz J., Tolnay M., Barmettler R., Ferrari A., Burki K., Goedert M., et al. (2001) Human tau transgenic mice, in Neuropathology and Genetics of Dementia (Tolnay M. and Probst A., eds.), Kluwer Academic/Plenum, New York.Google Scholar
- Reiman E. M., Caselli R. J., Chen K., Alexander G. E., Bandy D., and Frost J. (2001) Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 98, 3334–3339.PubMedCrossRefGoogle Scholar
- Small G. W., Rabins P. V., Barry P. P., Buckholtz N. S., DeKosky S. T., Ferris S. H., et al. (1997) Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 278, 1363–1371.PubMedCrossRefGoogle Scholar